The reasons cited were limited efficacy (about one additional sexually satisfying event per month), concerns about safety and potential adverse effects with long-term therapy, and concerns about inappropriate off-label use. In 2003, the FDA rejected Intrinsa, a 300 μg/day testosterone patch for the treatment of sexual dysfunction in postmenopausal women. For this reason, and due to the unknown health effects and safety of testosterone therapy, its use may be inappropriate. In contrast to these high doses, there is little support for the notion that testosterone is a critical hormone for sexual desire and function in women under normal physiological circumstances. Although testosterone has been found to be effective at improving sexual function in postmenopausal women, the doses employed have been supraphysiological.
